[{"id":"19131867-1550-4e69-800e-247cea563505","acronym":"KEYNOTE-B79","url":"https://clinicaltrials.gov/study/NCT04991948","created_at":"2021-08-05T13:53:08.839Z","updated_at":"2025-02-25T16:16:35.370Z","phase":"Phase 1","brief_title":"Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04991948 - KEYNOTE-B79","lead_sponsor":"Celyad Oncology SA","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/25/2038","study_completion_date":" 05/25/2038","last_update_posted":"2022-03-09"}]